Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Clinical Outcomes and Mutational Profile Associated with Dysmyelopoiesis in Chronic Myelomonocytic Leukemia

Xavier Calvo, David Román, Nieves Garcia Garcia-Gisbert, Concepción Fernández-Rodriguez, Marta Salido, Anna Puiggros, Blanca Espinet, Sara Garcia-Avila, Félix López Cadenas, Abora Rial-Villavecchia, Luis Colomo, Lourdes Florensa, Ana Ferrer, Leonor Arenillas

Blood (2023) 142 (Supplement 1): 3226.

https://doi.org/10.1182/blood-2023-185591

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Assessment of Dysgranulopoiesis By Optical Cytology Compared to Distribution of Monocyte Subsets By Flow Cytometry in Peripheral Blood for Predicting the Diagnosis of CMML

David Roman-Bravo, Leonor Arenillas, Aylin Vasquez, Lourdes Florensa, Beatriz Costan, Rosa Navarro, Martina Karasiewicz, Sara Garcia-Avila, Felix Lopez-Cadenas, Marta Salido, Anna Puiggros, Blanca Espinet, Ana Ferrer, Xavier Calvo

Blood (2022) 140 (Supplement 1): 12347–12348.

https://doi.org/10.1182/blood-2022-166229

Published: 2022

Journal Articles

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Maria Julia Montoro Gómez, Laura Palomo, Pablo Vidal, Francisco Fuster-Tormo, Esperanza Such, Margarita Ortega, Teresa González, Felix Lopez-Cadenas, Sara Garcia-Avila, Nieves Garcia-Gisbert, Elvira Mora Casterá, Eugenia Rivero, Francesc Bosch, Andrés Jerez, Maria Diez-Campelo, Francesc Solé, David Valcárcel

Blood (2022) 140 (Supplement 1): 6949–6951.

https://doi.org/10.1182/blood-2022-165257

Published: 2022

Journal Articles

Myelodysplastic Syndromes Presenting with Isolated Thrombocytopenia: A Less Aggressive Form of Presentation and with Better Prognosis

Marie Solange Flores-Moran, Leonor Arenillas, Ana Ferrer, Felix Lopez-Cadenas, Sara Garcia-Avila, Concepción Fernández, Antonio Salar, Xavier Calvo

Blood (2022) 140 (Supplement 1): 6960–6961.

https://doi.org/10.1182/blood-2022-167567

Published: 2022

Journal Articles

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Nieves Garcia-Gisbert, Brayan Merchan, Sara Garcia-Avila, Marta Salido, Concepción Fernández-Rodríguez, Joan Gibert, Lierni Fernández-Ibarrondo, Laura Camacho, Marta Lafuente, Raquel Longarón, Blanca Espinet, Patricia Vélez, Marcio M Andrade-Campos, Ramon M. Pujol, Leonor Arenillas, Xavier Calvo, Carles Besses, Antonio Salar, Beatriz Bellosillo

Blood (2021) 138 (Supplement 1): 2599.

https://doi.org/10.1182/blood-2021-148297

Published: 2021

Journal Articles

Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes

Nieves Garcia-Gisbert, Leonor Arenillas, David Roman-Bravo, Juan José Rodríguez-Sevilla, Brayan Merchan, Sara Garcia-Avila, Concepción Fernández-Rodríguez, Joan Gibert, Antonio Salar, Beatriz Bellosillo, Ana Ferrer, Xavier Calvo

Blood (2021) 138 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2021-152674

Published: 2021

Journal Articles

Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML)

David Roman-Bravo, Leonor Arenillas, Maria Teresa Asensi, Nieves Garcia-Gisbert, Juan Jose Rodriguez-Sevilla, Brayan Merchan, Sara García Ávila, Beatriz Bellosillo, Concepción Fernández-Rodríguez, Lourdes Florensa, Ana Ferrer, Xavier Calvo

Blood (2021) 138 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2021-146447

Published: 2021

Journal Articles

Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis-Associated Speck-like Protein (ASC) and Reverted By IL1β Inhibitors

Blood (2021) 138 (Supplement 1): 3670.

https://doi.org/10.1182/blood-2021-153686

Published: 2021

Journal Articles

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Marcio M Andrade-Campos, MD PhD, Lierni Fernández-Ibarrondo, Joan Gibert, PhD, Concepción Fernández, Brayan Merchan, MD, Nieves García Gisbert, BSc, Laura Camacho, Leonor Arenillas, MD PhD, Sara García Ávila, MD, Raquel Longarón, Antonio Salar, MD PhD, Carles Besses, MD PhD, Beatriz Bellosillo, PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142705

Published: 2020

Journal Articles

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Lucrecia Yanez San Segundo, MD PhD, Noemi Fernandez Escalada, MD, Arancha Bermúdez, MD, Guillermo Martín Sánchez, MD, Sara García Avila, MD, Mónica López Duarte, MD, Mercedes Colorado, MD, Iñigo Romon, MD PhD, Carlos Richard, MD, Enrique M. Ocio, MD PhD

Blood (2019) 134 (Supplement_1): 5655.

https://doi.org/10.1182/blood-2019-130731

Published: 2019

Journal Articles

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Cristina Fernández Martínez, Arancha Bermúdez, MD, Sara García Ávila, MD, Borja San Pedro, Almudena Cabero Martínez, MD, Lucrecia Yáñez, MD PhD, Mónica López Duarte, Mercedes Colorado, MD, Sonia González de Villambrosia, MD, Joan Manuel Mora, MD, Yolanda Gonzalez Romero, MD, David Gomez, MD, Sara Fenandez Luis, MD, Irati Ormazabal, MD, Andrés Insunza, Iñigo Romon, MD PhD, Jose Luis Arroyo, MD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2018-99-114124

Published: 2018

Journal Articles

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Joan Manuel Mora, MD, Arancha Bermúdez, MD, Miguel Angel Cortés, MD, Yolanda González Romero, MD, Mercedes Colorado, MD, Cristina Fernández Martínez, MD, Almudena Cabero Martínez, MD, David Gómez, MD, Sara Fernández Luis, MD, Sara García Ávila, MD, Lucrecia Yáñez, MD PhD, Irati Ormazabal, MD, Guillermo Martín Sánchez, MD, Jose Luis Arroyo, MD, Javier Núñez, MD, Iñigo Romón, MD PhD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2018-99-118664

Published: 2018

Journal Articles

Long-Term Results and Cost-Effectiveness of the Flagida-Lite Regimen in Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Almudena Cabero Martínez, Arancha Bermudez, Lucrecia Yañez, Andrés Insunza, Mercedes Araujo Colorado, PhD, Cristina Fernandez Martinez, Virginia Martinez Callejo, Teresa Bernal Del Castillo, MD PhD, Miriam Sánchez Escamilla, Mónica López Duarte, German Pérez Vázquez, Carmen Montes, Eulogio Conde, MD PhD, Maria Luisa Gutiérrez, Sara García Ávila, Mara Celis, Carlos Richard

Blood (2017) 130 (Supplement 1): 2614.

https://doi.org/10.1182/blood.V130.Suppl_1.2614.2614

Published: 2017

NARROW

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Clinical Outcomes and Mutational Profile Associated with Dysmyelopoiesis in Chronic Myelomonocytic Leukemia

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Assessment of Dysgranulopoiesis By Optical Cytology Compared to Distribution of Monocyte Subsets By Flow Cytometry in Peripheral Blood for Predicting the Diagnosis of CMML

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Myelodysplastic Syndromes Presenting with Isolated Thrombocytopenia: A Less Aggressive Form of Presentation and with Better Prognosis

Non-Invasive Genetic Profiling and Monitoring in Myelodysplastic Syndromes

Multiple TET2 Mutations As a New Biological Clue for Differentiating Oligomonocytic Chronic Myelomonocytic Leukemia from Myelodysplastic Syndromes

Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML)

Overactivation of the NLRP3 Inflammasome in Chronic Myelomonocytic Leukemia KRAS Mutated Patients Can be Detected By the Apoptosis-Associated Speck-like Protein (ASC) and Reverted By IL1β Inhibitors

Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Post-Transplantation Cyclophosphamide Versus Low Doses ATG Fresenius As Part of Two Immunosuppression Regimens for Graft Versus Host Disease Prophylaxis: Low Severe Graft Versus Host Disease (GVHD) Incidence and y Similar Gvhd-Free and Relapse-Free Survival (GRFS)

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Long-Term Results and Cost-Effectiveness of the Flagida-Lite Regimen in Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only